Nut Consumption and Cardiovascular Risk in Older Chinese: The Guangzhou Biobank Cohort Study

Yangbo Sun¹, Chao Qiang Jiang², Kar Keung Cheng³, Wei Sen Zhang², Gabriel M. Leung¹, Tai Hing Lam¹*, C. Mary Schooling¹,4

1 School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, SAR, China, 2 Guangzhou Number 12 Hospital, Guangzhou, China, 3 Department of Public Health and Epidemiology, University of Birmingham, Birmingham, United Kingdom, 4 School of Public Health, CUNY, New York City, New York, United States of America

* hmrth@hkucc.hku.hk

Abstract

Objectives
In Western contexts nut consumption is associated with better health. We examined the associations of nut consumption with cardiovascular disease risk in the non-Western setting of Southern China.

Methods
In the Guangzhou Biobank Cohort Study we used multivariable linear regression to examine the associations of baseline nut (mainly peanuts) consumption (none (n = 6688), <3 portions/week (n = 2596) and ≥3 portions/week (n = 2444)) with follow-up assessment of Framingham cardiovascular disease score (excluding smoking) and its components in older Chinese (≥50 years) (follow-up 57.8%).

Results
Nut consumption was not associated with Framingham score (≥3 portions/week compared to none: 0.02 95% confidence interval (CI) -0.11 to 0.15), systolic blood pressure (-0.66 mmHg 95% CI -1.94, 0.62), diastolic blood pressure (-0.69 mmHg 95% CI -1.44, 0.07), HDL-cholesterol (-0.01 mmol/L 95% CI -0.02, 0.005), LDL-cholesterol (-0.01 mmol/L 95% CI -0.05, 0.02) or fasting glucose (0.04 mmol/L 95% CI -0.02, 0.09), adjusted for baseline values, energy intake, age, sex, phase of recruitment, socio-economic position, lifestyle and baseline health status.

Conclusions
Observations concerning the benefits of nut consumption may be contextually specific, perhaps depending on the type of nut consumed.
Introduction

Nuts are promoted as part of a healthy diet [1]. Observational studies in Western settings have shown that nut consumption is negatively associated with cardiovascular disease (CVD), diabetes and mortality [2–5]. Long-term randomized controlled trials (RCTs) have shown that the Mediterranean diet, which is rich in nuts, reduces CVD or its risk factors [6, 7]. Some short-term RCTs also showed some protective effects of nut consumption on cardiovascular health, such as lower total and LDL-cholesterol and better glycemic control [8–10]. However, these dietary RCTs are difficult to interpret, because some of the interventions changed more than nut consumption and the type of nuts consumed varied [11]. Moreover, lack of compliance may bias RCTs towards the null.

Nuts are rich in unsaturated fatty acids, minerals (e.g., magnesium and potassium), fibers, plant proteins, and antioxidant vitamins (e.g., vitamin E) [12–14], although the benefits of unsaturated fats and vitamin E have been questioned [15, 16]. The observed associations of nut consumption with cardiovascular health could be the result of beneficial effects of nutrients in nuts, however, it could also be due to residual confounding by socio-economic position (SEP) or other lifestyle factors [17, 18]. Reverse causation is also possible as people might eat more nuts in response to poor health. Evidence from non-western settings with a potentially different confounding structure and diet may help identify whether these observed associations are biologically based or contextually specific results of unmeasured confounding.

To our knowledge no previous study has examined the associations of nut consumption with cardiovascular risk in China. We examined the prospective associations of nut consumption with Framingham score and CVD risk factors in a large study of older adults (50+ years) from the economically developing non-western setting of Guangzhou in Southern China, and whether the associations varied by health status. We also examined whether the associations varied by sex and among men by smoking status.

Materials and Methods

Ethics statement

The Guangzhou Medical Ethics Committee of the Chinese Medical Association approved the study and all participants gave written, informed consent before participation.

Participants

The baseline examination of Guangzhou Biobank Cohort Study (GBCS) was conducted from 2003 to 2008, and the follow-up from 2008 to 2012. Details of GBCS have been reported previously [19]. Briefly, GBCS is a 3-way collaboration between Guangzhou Number 12 Hospital and the Universities of Hong Kong and Birmingham, UK. Recruitment of participants was from “The Guangzhou Health and Happiness Association for the Respectable Elders” (GHHARE), a community social and welfare organization. GHHARE unofficially aligned with the municipal government. Membership is open to Guangzhou permanent residents aged 50 years or above for a nominal fee of 4 CNY (≈50 US cents) per month. GHHARE included about 7% of Guangzhou residents in this age group, with branches in all 10 districts of Guangzhou, the capital city of Guangdong province in southern China. Within sex and age group, the GBCS participants had fairly similar prevalence of chronic diseases, such as diabetes and hypertension, as a nationally representative sample of urban Chinese [19]. The baseline and follow-up examination included an interview concerning lifestyle, family and personal medical history and assessment of weight, height, waist circumference, blood pressure, fasting plasma...
glucose, lipids and inflammatory markers. Plasma glucose and lipids were measured by Roche COBAS automatic biochemical analyzer.

**Nut consumption**

Nut consumption was considered as 25 gram portions per week, obtained from a validated food frequency questionnaire (FFQ) used in phases 1 and 2, but not in phase 3 [19, 20]. The FFQ contained 300 food items, including 5 commonly eaten nuts from Southern China (chestnut, cashew, peanut, walnut and almonds). The participants were asked the usual amount and frequency of each nut consumed in the past week, with a usual serving size specified. Nut consumption was reported as portions per week and categorized into never, <3 portions/week and ≥3 portions/week, based on the frequency of consumption and the usual amount per occasion. The most commonly eaten nut was peanuts, consumed by 36% of the participants. For other types of nut, 10% of participants ever consumed walnuts, 5% ever consumed chestnuts, 2% ever consumed almonds and 1% ever consumed cashew nuts.

**Outcomes**

The primary outcome was the Framingham score from follow up stage [21] which predicts coronary heart disease (CHD) risk from sex, age, LDL-cholesterol, HDL-cholesterol, blood pressure, smoking and history of diabetes. We removed smoking from the score, so that it was not included, so as to examine the potential biological effect on these risk factors. A higher score predicts higher CHD risk, consistent with the updated risk assessment equations for atherosclerotic CVD in the 2013 American College of Cardiology and the American Heart Association guidelines [22]. The Framingham score over-estimates CVD risk in Chinese populations, but ranks correctly [23]. The secondary outcomes were components of the Framingham score.

**Health status**

We constructed a 9-item index to assess health status, similar to one previously used, which was strongly associated with mortality [24], by counting chronic conditions (self-reported heart disease, stroke, diabetes, chronic obstructive pulmonary disease (COPD) and/or asthma, and hypertension), use of health services (regular use of medication and any hospital admission in the last 6 months), cognitive impairment (delayed recall score of 3 or less out of 10), and weight loss of more than 2.5 kg in the last 12 months.

**Statistical analysis**

Multivariable linear regression was used to assess the adjusted associations of nut consumption with Framingham score, while multivariable censored linear regression was used to assess associations with blood pressure, lipids and fasting glucose, because people taking medications for hypertension (n = 3871), hyperlipidemia (n = 790) or diabetes (n = 1263) might result in lower blood pressure, LDL-cholesterol and fasting glucose than the true measure and higher HDL-cholesterol. These models censored the outcomes for those on medication at the observed value so that the true measurement for blood pressure, LDL-cholesterol and fasting glucose was assumed to be that observed or higher, while for HDL-cholesterol it was assumed to be that observed or lower. We included potential confounders sequentially. Model 1 adjusted for sex, age (in 5-year age groups), recruitment phase, baseline values of the same risk factor and total energy intake which was calculated from the food frequency questionnaire and dietary composition tables based on McCance and Widdowson [25] and the Chinese Medical Sciences Institute [26]. Model 2 additionally adjusted for life course SEP (father’s occupation, education,
longest-held occupation and household income per head) and lifestyle (smoking, alcohol use and physical activity). Model 3 additionally adjusted for health status. Model 4 additionally adjusted for body mass index (BMI) and waist-hip ratio (WHR), considering the unclear role of nut consumption in adiposity.

To assess reverse causality, we examined whether these associations varied by health status, because people in poor health consuming more nuts as a protective measure would generate different associations of nut consumption with CVD risk factors by health status. We assessed differences by health status from the heterogeneity across subgroups and the p-values of the relevant interaction terms in models including interactions with other confounders to avoid confounding by these other interactions. We also similarly examined whether the associations varied by sex, and among men by smoking status.

Information on exposures and potential confounders was missing for less than 5% apart from the longest-held occupation (14.21%) and father’s occupation (42.62%). Missing exposures and potential confounders were predicted based on a flexible additive regression model with predictive mean matching incorporating all exposures, potential confounders and outcomes. We imputed values 10 times and results from the 10 imputations were summarized into single estimated beta-coefficients with confidence intervals and p-values adjusted for the missing data uncertainty [27].

Sensitivity analysis
Given we previously found SEP was not clearly associated with CVD risk factors among men [28], we did a separate analysis for men, where confounding by socioeconomic factors might be less relevant.

Results
Of the original 20,305 participants in phases 1 (10389) and 2 (9916) of GBCS, till follow-up 18,569 were still alive, 1446 died and 290 had a status of unknown. Of the 18,569 alive and able to participate in the follow-up, 11,741 participated (63% response), and 11,728 had complete data on nut consumption and energy intake. Compared with those who did not participate in the follow-up, participants in the follow-up were younger, with higher education, a non-manual occupation (of self and father), less likely to be smokers or alcohol users, more physically active, had lower BMI and WHR, and were in better health.

There were more women (8399) than men (3329), and the women were younger (mean age 61.2 (standard deviation (SD) 6.4) than the men (mean age 64.2 (SD 6.2)). Their age ranged from 50 to 95 years, with only 207 participants older than 75 years. Nut consumption (25 gram portions per week) ranged from 0.0 to 70.0, and the median was 0.0 (mean consumption 1.6 (SD 3.0)), with 94% of participants eating less than 7 portions per week.

Greater nut consumption was associated with higher socio-economic position (education, non-manual occupation (of self and father) and higher personal income) for men and women (Table 1). Nut consumption had inconsistent associations with lifestyle and attributes of health, being positively associated with alcohol use, physical activity, and BMI, but was not associated with age, smoking status, WHR or health status.

Prospectively nut consumption was unrelated to Framingham score and its biological components (systolic blood pressure, diastolic blood, HDL-cholesterol, LDL-cholesterol and fasting glucose) (Table 2). These associations did not vary by health status or sex (p-values ≥0.12). Correspondingly, nut consumption was unrelated to Framingham score and its biological components among men only (Table 3), and these associations did not vary by health status or smoking status (p-values ≥0.07).
Table 1. Characteristics by Nut Consumption in Older Chinese (3329 men and 8399 women) in Phases 1 and 2 of the Guangzhou Biobank Cohort Study. Abbreviations: IPAQ, International Physical Activity Questionnaire; HEPA, health-enhancing physical activity, i.e., vigorous activity at least 3 days a week that corresponds to a minimum of 1500 metabolic equivalent (MET) minutes per week, or activity 7 days of the week that corresponds to at least 3000 MET minutes per week.

| Nut consumption (25g portions/week) | Men | Women |
|-------------------------------------|-----|-------|
| N                                  | 1956 | <3 653 | ≥3 725 | P value | 4738 | <3 1945 | ≥3 1724 | P value |
| Age group (%)                       |      |       |       |         |      |       |       |         |
| 50–54                               | 6.8  | 6.6   | 7.2   | 17.0    | 20.9 | 18.3  |       |         |
| 55–59                               | 20.1 | 22.5  | 18.1  | 28.3    | 32.3 | 30.9  |       |         |
| 60–64                               | 26.4 | 25.9  | 27.7  | 22.3    | 20.4 | 21.9  |       |         |
| 65–69                               | 27.4 | 25.1  | 28.4  | 21.4    | 16.9 | 19.8  |       |         |
| 70–74                               | 17.2 | 16.7  | 15.2  | 9.3     | 8.5  | 7.78  |       |         |
| 75–79                               | 1.6  | 2.8   | 3.0   | 1.5     | 0.8  | 1.2   |       |         |
| ≥80                                 | 0.5  | 0.5   | 0.4   | 0.37    | 0.2  | 0.1   | 0.1   | <0.001 |
| Education (%)                       |      |       |       |         |      |       |       |         |
| Less than primary school            | 2.7  | 1.7   | 1.7   | 12.8    | 9.5  | 8.2   |       |         |
| Primary school                      | 29.7 | 23.4  | 19.5  | 38.8    | 33.2 | 35.3  |       |         |
| Junior middle school                | 28.2 | 28.8  | 32.9  | 25.2    | 26.3 | 30.7  |       |         |
| Senior middle school                | 24.1 | 25.0  | 24.6  | 18.0    | 23.7 | 19.2  |       |         |
| Junior college                      | 8.6  | 10.7  | 12.0  | 3.5     | 5.0  | 4.4   |       |         |
| College or above                    | 6.8  | 10.4  | 9.4   | <0.001  | 1.8  | 2.4   | 2.2   | <0.001 |
| Father's occupation (%)             |      |       |       |         |      |       |       |         |
| Manual                              | 81.2 | 81.0  | 74.3  | 79.1    | 76.7 | 74.6  |       |         |
| Non-manual                          | 18.8 | 19.0  | 25.7  | 0.01    | 20.9 | 23.3  | 25.4  | 0.01   |
| Job type (%)                        |      |       |       |         |      |       |       |         |
| Manual                              | 57.4 | 47.8  | 46.2  | 78.2    | 73.8 | 71.4  |       |         |
| Non-manual                          | 42.6 | 52.0  | 53.8  | <0.001  | 21.8 | 26.2  | 28.6  | <0.001 |
| Income group (%)                    |      |       |       |         |      |       |       |         |
| < 10000 yuan                        | 24.3 | 20.7  | 18.8  | 47.7    | 38.3 | 38.6  |       |         |
| 10000 to 15000 yuan                 | 44.7 | 46.1  | 45.6  | 41.8    | 49.7 | 49.4  |       |         |
| ≥ 15000 yuan                        | 31.0 | 33.2  | 35.6  | 0.02    | 10.5 | 12.0  | 12.0  | <0.001 |
| Smoking status (%)                  |      |       |       |         |      |       |       |         |
| Never                               | 41.3 | 48.7  | 43.3  | 96.6    | 97.1 | 97.0  |       |         |
| Ex-smoker                           | 28.6 | 25.0  | 30.2  | 1.8     | 1.0  | 1.4   |       |         |
| Current smoker                      | 30.1 | 26.3  | 26.5  | 0.01    | 1.6  | 1.9   | 1.6   | 0.12   |
| Alcohol use (%)                     |      |       |       |         |      |       |       |         |
| Never                               | 64.1 | 56.9  | 53.9  | 91.1    | 87.8 | 85.6  |       |         |
| <1/month                            | 12.6 | 22.2  | 17.4  | 5.3     | 8.1  | 8.5   |       |         |
| <1/week                             | 4.3  | 5.4   | 6.9   | 1.1     | 1.5  | 1.8   |       |         |
| 1–4/week                            | 7.8  | 5.8   | 9.2   | 0.9     | 1.2  | 1.4   |       |         |
| >5/week                             | 8.6  | 7.9   | 10.9  | 1.2     | 0.8  | 1.9   |       |         |
| Ex-drinker                          | 2.7  | 1.7   | 1.7   | <0.001  | 0.3  | 0.6   | 0.8   | <0.001 |
| Physical activity (IPAQ) (%)        |      |       |       |         |      |       |       |         |
| Inactive                            | 10.1 | 9.2   | 5.7   | 9.9     | 6.4  | 4.9   |       |         |
| Minimally active                    | 46.5 | 44.9  | 50.2  | 45.0    | 48.6 | 46.0  |       |         |
| HEPA                                | 43.4 | 45.9  | 44.1  | 0.01    | 45.0 | 45.0  | 49.1  | <0.001 |
| Body mass index                     | 23.4 | 23.5  | 23.8  | 0.02    | 23.8 | 23.9  | 24.0  | 0.04   |

(Continued)
Discussion

This large prospective study from an under-studied non-western developing population showed no association of nut consumption, mainly peanuts, with Framingham score or its components. The results did not vary by baseline health status or sex, indicating these results were likely not due to changes in response to poor health.

Our results were inconsistent with 6 recent meta-analyses of observational studies from Western countries including prospective studies where nut consumption was found to be associated with lower cardiovascular risk including fewer CVD events and deaths [2–5, 29, 30], and 2 recent meta-analyses of RCTs where nut consumption reduced LDL-cholesterol and glucose [10, 31]. However, our study is consistent with the same meta-analyses of RCTs where nut consumption had no effect on HDL-cholesterol [10, 31], and an RCT where nut consumption was not associated with the risk of myocardial infarction [32]. Some dietary interventions included dietary changes involving more than increased nut consumption and used different types of nuts, which make these dietary RCTs difficult to interpret.

Several explanations for our findings are plausible. Observational studies are vulnerable to residual confounding by SEP, lifestyle and other dietary items. Observational studies in a different population, with justifiable adjustment for confounders, may help verify causality. In China, as in western studies, greater nut consumption was associated with higher SEP and some aspects of a healthier lifestyle [17, 18]. However, our observation that overall nut consumption was not associated with Framingham score or its components is inconsistent with most studies including observational studies from western countries, where nut consumption is usually associated with lower risk of developing CVD. Moreover, in our population for men where there might be less confounding by SEP [28], nut consumption was also not associated with CHD risk factors, indicating confounding by SEP is less likely in our study. Thus differences between the results from our study and western studies may have arisen because our observations are less confounded.

Another possibility is reverse causation, if people in poor health might eat more nuts. In some observational studies in Western countries, the negative associations of nut consumption with CVD risk was attenuated after adjusting for health status suggesting that the observed associations could partially be due to reverse causality [33, 34]. Here we specifically took advantage of our large study to assess reverse causality by examining if associations differed by health status. However, in our study the associations of nut consumption with Framingham score and its components did not vary by health status, indicating reverse causation is unlikely.
Table 2. Adjusted Associations of Nut Consumption with Framingham Risk Score and CVD Risk Factors after Multiple Imputation in Older Chinese in Phases 1 and 2 of the Guangzhou Biobank Cohort Study.

| Model | n     | Nut consumption (25g portions/week) | P-value for trend | P-value for interaction by sex | P-value for interaction by health status |
|-------|-------|-------------------------------------|-------------------|--------------------------------|------------------------------------------|
|       |       | 0 (n = 6688)                        | 0 <3 (n = 2596)   | ≥3 (n = 2444)               |                                          |
| Framingham Risk Score |       | coefficient | 95% CI  | coefficient | 95% CI  |                                          |
| 1     | 11495 | reference | 0.10 | -0.02, 0.23 | -0.002 | -0.13, 0.13 | 0.44 | 0.14 | 0.23 |
| 2     | 11495 | reference | 0.13 | 0.01, 0.26 | 0.02 | -0.11, 0.15 |                                          |
| 3     | 11495 | reference | 0.13 | 0.01, 0.26 | 0.02 | -0.11, 0.15 |                                          |
| 4     | 11495 | reference | 0.14 | 0.02, 0.26 | 0.01 | -0.12, 0.13 |                                          |
|       |       | Systolic blood pressure (mm Hg) |                   |                                |                                          |
| 1     | 11592 | reference | -0.59 | -1.81, 0.63 | -0.62 | -1.89, 0.65 | 0.26 | 0.69 | 0.34 |
| 2     | 11592 | reference | -0.64 | -1.87, 0.60 | -0.64 | -1.92, 0.64 |                                          |
| 3     | 11592 | reference | -0.55 | -1.78, 0.68 | -0.66 | -1.94, 0.62 |                                          |
| 4     | 11592 | reference | -0.51 | -1.73, 0.72 | -0.68 | -1.95, 0.60 |                                          |
|       |       | Diastolic blood pressure (mm Hg) |                   |                                |                                          |
| 1     | 11595 | reference | -0.63 | -1.35, 0.09 | -0.61 | -1.35, 0.14 | 0.04 | 0.18 | 0.77 |
| 2     | 11595 | reference | -0.65 | -1.37, 0.08 | -0.63 | -1.38, 0.13 |                                          |
| 3     | 11595 | reference | -0.64 | -1.36, 0.09 | -0.69 | -1.44, 0.07 |                                          |
| 4     | 11595 | reference | -0.69 | -1.42, 0.03 | **-0.82** | -1.57, -0.07 |                                          |
|       |       | HDL-cholesterol (mmol/L) |                   |                                |                                          |
| 1     | 11526 | reference | **-0.02** | -0.03, -0.004 | -0.01 | -0.03, 0.004 | 0.07 | 0.51 | 0.25 |
| 2     | 11526 | reference | **-0.02** | -0.03, -0.004 | -0.01 | -0.03, 0.004 |                                          |
| 3     | 11526 | reference | **-0.02** | -0.03, -0.004 | -0.01 | -0.02, 0.005 |                                          |
| 4     | 11526 | reference | **-0.02** | -0.03, -0.004 | -0.01 | -0.02, 0.01 |                                          |
|       |       | LDL-cholesterol (mmol/L) |                   |                                |                                          |
| 1     | 11519 | reference | 0.004 | -0.03, 0.04 | -0.02 | -0.05, 0.01 | 0.54 | 0.12 | 0.29 |
| 2     | 11519 | reference | 0.01 | -0.02, 0.04 | -0.01 | -0.05, 0.02 |                                          |
| 3     | 11519 | reference | 0.01 | -0.02, 0.04 | -0.01 | -0.05, 0.02 |                                          |
| 4     | 11519 | reference | 0.01 | -0.02, 0.04 | -0.02 | -0.05, 0.02 |                                          |

(Continued)
We were unable to measure the changes of nut consumption over time, thus it is possible that the associations of nut consumption with cardiovascular risk factors were unobserved if the effect of nut consumption is short-term. The relatively small proportion of large amounts of nut consumption in our population might make it difficult to observe the effect of nuts on cardiovascular risk if high nut consumption is necessary. However, there is no reason to think that nut consumption above a certain threshold is necessary before benefits occur and our large sample makes it possible to detect relatively small effects even within a small range of nut consumption.

Finally, we cannot rule out the possibility that our population were eating the wrong sort of nuts. Peanuts were the type of nuts most commonly consumed, and peanuts are members of the legume family as distinct from tree nuts, such as almonds, walnuts and cashew nuts. Both legumes and tree nuts are part of a healthy diet, although the evidence from RCTs for tree nuts and peanuts is limited and somewhat inconsistent [10, 35]. Nevertheless, the benefits of nuts could be restricted to tree nuts.

The strengths of our study included the prospective design, a large sample from an understudied population, whose lifetime experiences were typical of much of the global population from middle and low income countries. Nevertheless, some limitations exist. First, our participants were not a randomly selected, representative sample. However, sample selection should not affect internal associations, unless we missed people with specific combinations of nut consumption and CVD risk. Moreover, when we used inverse probability weighting (IPW) to account for the difference between the original sample and the sample who returned for follow-up, the results were similar (data not shown). Second, we used a single measure of recalled nut consumption. Any non-differential misclassification would likely underestimate the true effects. Systematic recall bias by CVD risk factors is unlikely as participants were unaware of this hypothesis at the time of interview. Third, we were unable to check the influence of nut preparation (e.g., salted, spiced, roasted, or raw) on cardiovascular risk as we lacked data on how nuts were prepared. Finally, we considered the change in CVD risk between baseline and follow-up on the basis that nut consumption at baseline should change risk. However, if

| Model | n | Nut consumption (25g portions/week) | 0 (n = 6688) | <3 (n = 2596) | ≥3 (n = 2444) |
|-------|---|-----------------------------------|-------------|-------------|-------------|
|       |   | coefficient | 95% CI | coefficient | 95% CI | P-value for trend | P-value for interaction by sex | P-value for interaction by health status |
| 1     | 11685 | reference | 0.03 | -0.02, 0.08 | 0.04 | -0.02, 0.09 | 0.11 | 0.36 | 0.54 |
| 2     | 11685 | reference | 0.03 | -0.02, 0.09 | 0.04 | -0.01, 0.09 | 0.11 | 0.36 | 0.54 |
| 3     | 11685 | reference | 0.03 | -0.02, 0.09 | 0.04 | -0.02, 0.09 | 0.11 | 0.36 | 0.54 |
| 4     | 11685 | reference | 0.04 | -0.02, 0.09 | 0.04 | -0.02, 0.09 | 0.11 | 0.36 | 0.54 |

aMultivariable linear regression was used for Framingham risk score; multivariable censored linear regression was used for blood pressure, cholesterol and glucose.
bModel 1 adjusted for same factor at baseline, age, sex, daily energy intake and phase; Model 2 additionally adjusted for SEP (education, father’s occupation, longest-held occupation and personal income) and lifestyle (smoking status, alcohol use and physical activity); Model 3 additionally adjusted for baseline health status; Model 4 additionally adjusted for body mass index and waist-hip ratio.
cCoefficient means changes in risk score; bold values indicate P<0.05.

doi:10.1371/journal.pone.0137178.t002
Table 3. Adjusted Associations of Nut Consumption with Framingham Risk Score and CVD Risk Factors after Multiple Imputation in Older Chinese Men in Phases 1 and 2 of the Guangzhou Biobank Cohort Study.

| Model | n   | Nut consumption (25g portions/week) | P-value for trend | P-value for interaction by health status | P-value for interaction by smoking status |
|-------|-----|-------------------------------------|------------------|------------------------------------------|------------------------------------------|
|       |     | 0 (n = 1952)                        | <3 (n = 653)     | ≥3 (n = 724)                              |                                          |
|       |     | coefficient | 95% CI | coefficient | 95% CI | coefficient | 95% CI | coefficient | 95% CI |
| Framingham Risk Score | | | | | | | | | |
| 1    | 3262 | reference | -0.08 | -0.25, 0.09 | 0.05 | -0.12, 0.22 | 0.48 | 0.38 | 0.65 |
| 2    | 3262 | reference | -0.05 | -0.22, 0.12 | 0.08 | -0.08, 0.25 | 0.48 | 0.38 | 0.65 |
| 3    | 3262 | reference | -0.05 | -0.23, 0.11 | 0.06 | -0.10, 0.23 | 0.48 | 0.38 | 0.65 |
| 4    | 3262 | reference | -0.06 | -0.23, 0.11 | 0.06 | -0.10, 0.23 | 0.48 | 0.38 | 0.65 |
| Systolic blood pressure (mm Hg) | | | | | | | | | |
| 1    | 3282 | reference | -1.76 | -4.33, 0.82 | -0.16 | -2.70, 2.37 | 0.47 | 0.38 | 0.99 |
| 2    | 3282 | reference | -2.16 | -4.76, 0.43 | -0.52 | -3.08, 2.05 | 0.47 | 0.38 | 0.99 |
| 3    | 3282 | reference | -1.97 | -4.56, 0.62 | -0.54 | -3.10, 2.02 | 0.47 | 0.38 | 0.99 |
| 4    | 3282 | reference | -2.07 | -4.64, 0.51 | -0.68 | -3.23, 1.88 | 0.47 | 0.38 | 0.99 |
| Diastolic blood pressure (mm Hg) | | | | | | | | | |
| 1    | 3284 | reference | -1.75 | -3.59, 0.09 | -0.77 | -2.59, 1.04 | 0.13 | 0.37 | 0.79 |
| 2    | 3284 | reference | -1.94 | -3.80, -0.08 | -0.99 | -2.83, 0.86 | 0.13 | 0.37 | 0.79 |
| 3    | 3284 | reference | -1.83 | -3.69, 0.03 | -1.09 | -2.93, 0.76 | 0.13 | 0.37 | 0.79 |
| 4    | 3284 | reference | -1.89 | -3.75, -0.03 | -1.27 | -3.11, 0.58 | 0.13 | 0.37 | 0.79 |
| HDL-cholesterol (mmol/L) | | | | | | | | | |
| 1    | 3276 | reference | -0.001 | -0.03, 0.03 | -0.01 | -0.04, 0.01 | 0.37 | 0.56 | 0.71 |
| 2    | 3276 | reference | -0.01 | -0.03, 0.02 | -0.01 | -0.04, 0.01 | 0.37 | 0.56 | 0.71 |
| 3    | 3276 | reference | -0.01 | -0.03, 0.02 | -0.01 | -0.04, 0.01 | 0.37 | 0.56 | 0.71 |
| 4    | 3276 | reference | -0.001 | -0.03, 0.02 | -0.01 | -0.03, 0.02 | 0.37 | 0.56 | 0.71 |
| LDL-cholesterol (mmol/L) | | | | | | | | | |
| 1    | 3274 | reference | -0.05 | -0.11, 0.02 | -0.01 | -0.07, 0.05 | 0.81 | 0.79 | 0.66 |
| 2    | 3274 | reference | -0.04 | -0.10, 0.02 | 0.002 | -0.06, 0.06 | 0.81 | 0.79 | 0.66 |
| 3    | 3274 | reference | -0.04 | -0.10, 0.02 | 0.002 | -0.06, 0.06 | 0.81 | 0.79 | 0.66 |
| 4    | 3274 | reference | -0.04 | -0.10, 0.02 | 0.003 | -0.06, 0.06 | 0.81 | 0.79 | 0.66 |

(Continued)
baseline nut consumption represents lifelong habits it might be better to examine the association of baseline nut consumption with subsequent CVD risk. The association of baseline nut consumption with Framingham score and its components were similarly null, except nut consumption was positively associated with glucose (Tables C and D in S1 File). However, people who consumed nuts more than 3 portions/week had fasting glucose 0.2 mmol/L higher than people who never consumed nuts on average. Small effect sizes are meaningful at a population level, however an effect size of 0.2 would only represent a very small change in fasting glucose.

It is increasingly apparent that associations between dietary items and cardiovascular disease observed in western settings may reflect correlation rather than causation. Specifically some of the nutrients in nuts, such as unsaturated fats, vitamin E and magnesium have had potentially protective observations with various aspects of cardiovascular health or overall health refuted by RCTs [15, 36, 37]. Thus it is quite plausible that peanuts and/or tree nuts also have no relation with cardiovascular disease, which is only evident in a setting, such as ours, with a different pattern of confounding. In addition, salt may be introduced during the processing of nuts, which might counteract any small benefits of nuts [38].

From a public health perspective, the difficulties of identifying a healthy diet from observed associations are becoming increasingly obvious, consistent with the lack of association of nut consumption with CVD risk in a different setting. Dietary recommendations may need to be based on experimental evidence and should strike a balance between the potential benefits and harms of a certain food, or food pattern.

**Conclusion**

Our study is not consistent with western findings that nut consumption can protect against CVD or its risk factors. As with all observational studies these findings should be interpreted cautiously. Given the multi-factorial etiology of CVD, investigation of the underlying factors driving potential health benefits or harms of nuts might facilitate identification of a healthy diet for testing.

---

**Table 3.** (Continued)

| Model | n   | Nut consumption (25g portions/week) | P-value for trend | P-value for interaction by health status | P-value for interaction by smoking status |
|-------|-----|------------------------------------|-------------------|-----------------------------------------|-----------------------------------------|
|       |     | 0 (n = 1952) | <3 (n = 653) | ≥3 (n = 724) | coefficient | 95% CI | coefficient | 95% CI | coefficient | 95% CI | coefficient | 95% CI |
| Fasting plasma glucose (mmol/L) |     |                                 |                   |                  |            |     |                       |         |            |     |                      |         |
| 1     | 3316 | reference | -0.03 | -0.13, 0.07 | 0.05 | -0.05, 0.15 | 0.47 | 0.74 | 0.07 |
| 2     | 3316 | reference | -0.03 | -0.13, 0.07 | 0.03 | -0.05, 1.15 | 0.74 | 0.07 |
| 3     | 3316 | reference | -0.02 | -0.12, 0.08 | 0.05 | -0.05, 0.14 | 0.14 | 0.74 |
| 4     | 3316 | reference | -0.03 | -0.13, 0.07 | 0.04 | -0.05, 0.14 | 0.14 | 0.74 |

*a* Multivariable linear regression was used for Framingham risk score; multivariable censored linear regression was used for blood pressure, cholesterol and glucose.

*b* Model 1 adjusted for same factor at baseline, age, daily energy intake and phase; Model 2 additionally adjusted for SEP (education, father’s occupation, longest-held occupation and personal income) and lifestyle (smoking status, alcohol use and physical activity); Model 3 additionally adjusted for baseline health status: Model 4 additionally adjusted for body mass index and waist-hip ratio.

doi:10.1371/journal.pone.0137178.t003
Supporting Information

S1 File. Supporting tables. Table A in S1 File Characteristics by Participants and Non-participants during Follow-up in Phases 1 and 2 of the Guangzhou Biobank Cohort Study. Table B in S1 File Framingham Score and Its Components by Nut Consumption in Older Chinese (3329 men and 8399 women) in Phases 1 and 2 of the Guangzhou Biobank Cohort Study. Table C in S1 File Adjusted Associations of Nut Consumption with Framingham Risk Score and CVD Risk Factors after Multiple Imputation in Older Chinese in Phases 1 and 2 of the Guangzhou Biobank Cohort Study (without adjusting for the same factors at baseline). Table D in S1 File Adjusted Associations of Nut Consumption with Framingham Risk Score and CVD Risk Factors after Multiple Imputation in Older Chinese Men in Phases 1 and 2 of the Guangzhou Biobank Cohort Study (without adjusting for the same factors at baseline)

Acknowledgments

The Guangzhou Biobank Cohort Study investigators include: Guangzhou No. 12 Hospital: WS Zhang, M Cao, T Zhu, B Liu, CQ Jiang (Co-PI); The University of Hong Kong: CM Schooling, SM McGhee, GM Leung, R Fielding, TH Lam (Co-PI); The University of Birmingham: P Adab, GN Thomas, KK Cheng (Co-PI). This work was supported by the University of Hong Kong Foundation for Development and Research, Hong Kong; The University of Hong Kong University Research Committee Strategic Research Theme Public Health, Hong Kong; Guangzhou Public Health Bureau, and Guangzhou Science and Technology Committee, Guangzhou, China; and The University of Birmingham, Birmingham, UK. Key technology collaboration project funded by the Bureau of Guangzhou Science and Technology (Grant 2012J5100041; 2013J4100031). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

Conceived and designed the experiments: CQJ THL KKC. Performed the experiments: YS CMS GML. Analyzed the data: YS CMS GML. Contributed reagents/materials/analysis tools: WSZ. Wrote the paper: YS CMS.

References

1. The American Heart Association's Diet and Lifestyle Recommendations. 2014; Available: http://www.heart.org/HEARTORG/GettingHealthy/NutritionCenter/HealthyEating/The-American-HeartAssociations-Diet-and-Lifestyle-Recommendations_UCM_305855_Article.jsp.
2. Luo C, Zhang Y, Ding Y, et al. Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis. Am J Clin Nutr 2014; 100(1):256–69. doi: 10.3945/ajcn.113.076109 PMID: 24847854
3. Zhou D, Yu H, He F, et al. Nut consumption in relation to cardiovascular disease risk and type 2 diabetes: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr 2014; 100(1):270–77. doi: 10.3945/ajcn.113.079152 PMID: 24808491
4. Yun-Qi Weng JY, Ming-Lei Guo, Guoming Zhang and Peng Li. Association Between Nut Consumption and Coronary Heart Disease: a Meta-analysis. Experimental & Clinical Cardiology 2014; 20(6):3770–87.
5. Shi ZQ, Tang JJ, Wu H, et al. Consumption of nuts and legumes and risk of stroke: A meta-analysis of prospective cohort studies. Nutr Metab Cardiovasc Dis 2014;1–10. doi: 10.1016/j.numecd.2014.06.009 PMID: 25154028
6. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99(6):779–85. PMID: 9989963
7. Elhayany A, Lustman A, Abel R, et al. A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study. Diabetes Obesity & Metabolism 2010; 12(3):204–09.

8. Colpo E, Vilanova CD, Brenner Reetz LG, et al. A single consumption of high amounts of the Brazil nuts improves lipid profile of healthy volunteers. J Nutr Metab 2013; 2013:1–7.

9. Li SC, Liu YH, Liu JF, et al. Almond consumption improved glycemic control and lipid profiles in patients with type 2 diabetes mellitus. Metabolism 2011; 60(4):474–9. doi: 10.1016/j.metabol.2010.04.009 PMID: 20580779

10. Blanco Mejia S, Kendall CW, Viguiliouk E, et al. Effect of tree nuts on metabolic syndrome criteria: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2014; 4(7):e004660. doi: 10.1136/bmjopen-2013-004660 PMID: 25074070

11. Freudenheim JL. Study design and hypothesis testing: issues in the evaluation of evidence from research in nutritional epidemiology. Am J Clin Nutr 1999; 69(6):1315S–21S. PMID: 10359232

12. Kris-Etherton PM, Hu FB, Ros E, et al. The role of tree nuts and peanuts in the prevention of coronary heart disease: multiple potential mechanisms. J Nutr 2008; 138(9):1746S–51S. PMID: 18716180

13. Blomhoff R, Carlsen MH, Andersen LF, et al. Health benefits of nuts: potential role of antioxidants. British Journal of Nutrition 2006; 96(1):S52–S60.

14. Gonzalez CA, Salas-Salvado J. The potential of nuts in the prevention of cancer. Br J Nutr 2006; 96 Suppl 2:S87–94. PMID: 17125538

15. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008; 300(18):2123–33. doi: 10.1001/jama.2008.600 PMID: 18997197

16. Chowdhury R, Warnakula S, Kunutsor S, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med 2014; 160(8):398–406. doi: 10.7326/M13-1788 PMID: 24720379

17. Fraser GE, Sabate J, Beeson WL, et al. A Possible Protective Effect of Nut Consumption on Risk of Coronary Heart-Disease—The Adventist Health Study. Archives of Internal Medicine 1992; 152(7):1416–24. PMID: 1627021

18. Villegas R, Gao YT, Yang G, et al. Legume and soy food intake and the incidence of type 2 diabetes in the Shanghai Women’s Health Study. Am J Clin Nutr 2008; 87(1):162–7. PMID: 18175751

19. Jiang CQ, Thomas GN, Lam TH, et al. Cohort Profile: The Guangzhou Biobank Cohort Study, a Guangzhou-Hong Kong-Birmingham collaboration. International Journal of Epidemiology 2006; 35(4):S87–S60. PMID:16844769

20. Hsu-Hage BH, Wahlgvist ML. A food frequency questionnaire for use in Chinese populations and its validation. Asia Pac J Clin Nutr 1992; 1(4):211–23. PMID: 24323237

21. Wilson PWF, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18):1837–47. PMID: 9603539

22. Goff DC Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013.

23. Liu J, Hong YL, D’Agostino RB, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study. Jama-Journal of the American Medical Association 2004; 291(21):2591–99.

24. Schooling CM, Lam TH, Li ZB, et al. Obesity, physical activity, and mortality in a prospective chinese elderly cohort. Arch Intern Med 2006; 166(14):1498–504. PMID: 16864760

25. Holland B., Welch A. J., Unwin I. D., et al. McCance and Widdowson's The Composition of Foods. Fifth ed: The Royal Society of Chemistry and Ministry of Agriculture, Fisheries and Food; 1991.

26. China Food Composition 2002. Institute of Nutrition & Food Safety, China CDC: University Medical Press: Peking, China; 2002.

27. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999; 8(1):3–15. PMID: 10347857

28. Elwell-Sutton T, Jiang CQ, Zhang WS, et al. Socioeconomic Influences at Different Life Stages on Self-Rated Health in Guangzhou. Journal of Epidemiology and Community Health 2011; 65:A331–A331.

29. Afshin A, Micha R, Khatibzadeh S, et al. Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis. Am J Clin Nutr 2014; 100(1):278–88. doi: 10.3945/ajcn.113.076901 PMID: 24988241

30. Ma L, Wang F, Guo W, et al. Nut consumption and the risk of coronary artery disease: A dose-response meta-analysis of 13 prospective studies. Thromb Res 2014.
31. Sabate J, Oda K, Ros E. Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials. Arch Intern Med 2010; 170(9):821–7. doi: 10.1001/archinternmed.2010.79 PMID: 20458092

32. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368(14):1279–90. doi: 10.1056/NEJMoa1200303 PMID: 23432189

33. Ellsworth JL, Kushi LH, Folsom AR. Frequent nut intake and risk of death from coronary heart disease and all causes in postmenopausal women: The Iowa Women's Health Study. Nutrition Metabolism and Cardiovascular Diseases 2001; 11(6):372–77.

34. Li TY, Brennan AM, Wedick NM, et al. Regular Consumption of Nuts Is Associated with a Lower Risk of Cardiovascular Disease in Women with Type 2 Diabetes. Journal of Nutrition 2009; 139(7):1333–38. doi: 10.3945/jn.108.103622 PMID: 19420347

35. Ghadimi Nouran M, Kimiagar M, Abadi A, et al. Peanut consumption and cardiovascular risk. Public Health Nutr 2010; 13(10):1581–6. doi: 10.1017/S1368980009992837 PMID: 20025830

36. Ramsden CE, Zamora D, Leelarthaepin B, et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. Bmj-British Medical Journal 2013; 346.

37. Schuitemaker GE, van der Pol GA, Aretz CPM, et al. A placebo-controlled, double-blind, randomised trial of magnesium-pyridoxal-5'-phosphate-glutamate for hypercholesterolaemia and other clinical-chemical risk factors of cardiovascular disease in a primary care setting. European Journal of Clinical Pharmacology 2001; 56(12):857–63. PMID: 11317472

38. Martinez-Lapiscina EH, Pimenta AM, Beunza JJ, et al. Nut consumption and incidence of hypertension: the SUN prospective cohort. Nutr Metab Cardiovasc Dis 2010; 20(5):359–65. doi: 10.1016/j.numecd.2009.04.013 PMID: 19683907